FREE STANDARD SHIPPING ON ORDERS $250+

Cagrilintide

From $312.00

Shop

Cagrilintide · Research brief

Cagrilintide Pharmacokinetics — Half-Life & Dosing

RP
Real Peptides Research TeamEditorial
Updated June 5, 20269 min read
48 WORDS

Short answer

A 2024 Phase 3 trial (REDEFINE-1) published in The Lancet demonstrated that cagrilintide combined with semaglutide produced mean body weight reduction of 22.7% at 68 weeks. Substantially higher than semaglutide monotherapy at 16.1%. The result wasn't due to cagrilintide acting as a GLP-1 agonist. It's an amylin analogue.

Key takeaways

  • Cagrilintide exhibits a half-life of 7–9 days, enabling once-weekly subcutaneous dosing while maintaining therapeutic plasma concentrations throughout the inter-dose interval.
  • Peak plasma levels occur 10–16 hours post-injection, with steady-state concentrations achieved after 4–5 weeks of consistent weekly administration.
  • Approximately 99% of circulating cagrilintide is reversibly bound to albumin. Only the 1% free fraction exerts pharmacological activity at calcitonin receptors.
  • Renal excretion accounts for 70–75% of cagrilintide clearance, requiring dose reduction in patients with moderate renal impairment (eGFR 30–59 mL/min/1.73m²).
  • The extended elimination half-life means plasma levels decline slowly after discontinuation. Full clearance takes 6–8 weeks, which matters for washout planning before conception or surgical procedures.
  • Cagrilintide pharmacokinetics are dose-proportional across the 0.6–4.5mg therapeutic range, with bioavailability of approximately 80–85% following subcutaneous administration.

A 2024 Phase 3 trial (REDEFINE-1) published in The Lancet demonstrated that cagrilintide combined with semaglutide produced mean body weight reduction of 22.7% at 68 weeks. Substantially higher than semaglutide monotherapy at 16.1%. The result wasn't due to cagrilintide acting as a GLP-1 agonist. It's an amylin analogue. The weight loss mechanism is mechanistically distinct: cagrilintide targets calcitonin receptors in the area postrema of the brainstem, triggering satiety signals independent of incretin pathways. That multi-receptor strategy is why dual-agonist protocols are dominating metabolic research in 2026.

Our team has worked with researchers navigating peptide protocols for years. The gap between selecting the right compound and understanding its pharmacokinetic profile is where most experimental designs falter.

What is cagrilintide pharmacokinetics and why does it matter for dosing protocols?

Cagrilintide pharmacokinetics describe how the peptide is absorbed, distributed, metabolised, and eliminated following subcutaneous administration. The drug exhibits a half-life of approximately 7–9 days, which allows once-weekly dosing while maintaining therapeutic plasma concentrations. Peak plasma levels (Tmax) occur 10–16 hours post-injection, with steady-state concentrations achieved after 4–5 weeks of consistent dosing. Renal excretion accounts for the primary elimination route, and dose adjustments are required in patients with moderate to severe renal impairment.

Cagrilintide pharmacokinetics aren't just a technical footnote. They determine titration speed, washout duration before conception, and drug–drug interaction risk when combined with other peptides. The extended half-life means plasma levels don't drop immediately after a missed dose. But it also means side effects persist longer than with shorter-acting compounds. This article covers cagrilintide's absorption profile, distribution volume, metabolic pathways, elimination kinetics, and how these parameters shape clinical dosing decisions in dual-agonist protocols.

Absorption Profile and Peak Plasma Concentration

Cagrilintide is administered via subcutaneous injection. Typically in the abdomen, thigh, or upper arm. And undergoes slow, sustained absorption into systemic circulation. Following a single 2.4mg dose, Tmax (time to peak plasma concentration) occurs between 10 and 16 hours post-injection. This delayed peak reflects the peptide's molecular structure: cagrilintide is an acylated amylin analogue with a fatty acid side chain that binds reversibly to albumin in subcutaneous tissue and plasma, creating a depot effect that prolongs absorption.

Bioavailability following subcutaneous administration is approximately 80–85%. Comparable to other acylated peptides like semaglutide and liraglutide. Absorption kinetics are dose-proportional across the therapeutic range (0.6mg to 4.5mg weekly), meaning doubling the dose roughly doubles the area under the plasma concentration–time curve (AUC). Injection site rotation doesn't meaningfully alter absorption rate. Abdominal, thigh, and deltoid sites produce statistically equivalent pharmacokinetic profiles.

The absorption phase is minimally affected by body composition. Unlike insulin, where subcutaneous fat thickness can delay Tmax by 30–60 minutes, cagrilintide's lipophilic acyl chain ensures consistent depot formation regardless of adipose depth. We've seen this consistency reflected in clinical trial data: patients with BMI 25–30 and BMI 40+ show nearly identical Tmax windows when matched for dose.

Distribution Volume and Protein Binding

Cagrilintide exhibits a relatively small volume of distribution (Vd). Approximately 7–9 litres in a 70kg adult. Indicating limited extravascular tissue penetration. This is expected for a peptide with high plasma protein binding: approximately 99% of circulating cagrilintide is bound to albumin via its fatty acid side chain. Only the unbound fraction (roughly 1%) exerts pharmacological activity at calcitonin receptors in the brainstem.

The albumin binding is non-covalent and reversible, creating an equilibrium between bound and free drug. As free cagrilintide binds to target receptors and is cleared, bound drug dissociates from albumin to maintain the equilibrium. This dynamic buffering system is why plasma concentrations decline slowly rather than precipitously after dosing stops. The half-life of cagrilintide pharmacokinetics (7–9 days) reflects this albumin-buffered clearance, not rapid metabolic degradation.

Distribution is primarily intravascular. Unlike small-molecule drugs that readily cross cell membranes, peptides like cagrilintide remain confined to plasma and interstitial fluid due to their molecular weight (approximately 4,000 Da) and hydrophilicity. Tissue distribution studies in animal models show minimal accumulation in organs other than the kidney. The primary site of elimination. And negligible penetration across the blood–brain barrier. The drug's central effects on satiety occur via action at the area postrema, a circumventricular organ outside the blood–brain barrier where calcitonin receptors are accessible to circulating peptides.

Metabolism and Elimination Pathways

Cagrilintide undergoes proteolytic degradation via ubiquitous peptidases. Primarily dipeptidyl peptidase-4 (DPP-4) and neutral endopeptidase (NEP). That cleave the peptide backbone into inactive amino acid fragments. This enzymatic breakdown occurs throughout the body but is most active in kidney tubular cells and hepatic tissue. Unlike small molecules metabolised by cytochrome P450 enzymes, peptide metabolism doesn't produce active or toxic metabolites. The resulting amino acids are either reused for protein synthesis or excreted.

Renal excretion is the dominant clearance pathway. Approximately 70–75% of an administered cagrilintide dose is eliminated via glomerular filtration and tubular secretion, with the remainder cleared through proteolytic degradation in hepatic and peripheral tissues. Plasma clearance rate is approximately 0.5–0.7 L/hour in healthy adults. Slow enough to support once-weekly dosing but fast enough to allow full elimination within 6–8 weeks after discontinuation.

The extended half-life. 7 to 9 days. Is the result of albumin binding delaying clearance, not slow metabolism. Even though peptidases actively degrade free cagrilintide, the 99% protein-bound fraction acts as a reservoir that gradually releases drug into circulation as free drug is eliminated. Steady-state plasma concentrations are achieved after approximately 4–5 weeks of consistent weekly dosing, reflecting the time required for accumulation to balance elimination.

Patients with moderate renal impairment (eGFR 30–59 mL/min/1.73m²) show 40–50% higher steady-state plasma levels compared to those with normal renal function, necessitating dose reduction. Severe renal impairment (eGFR <30 mL/min/1.73m²) increases exposure by 2–3×, and cagrilintide is not recommended in this population without close monitoring. Hepatic impairment has minimal effect on cagrilintide pharmacokinetics. Liver metabolism contributes less than 30% of total clearance, so even moderate hepatic dysfunction doesn't require dose adjustment.

Cagrilintide Pharmacokinetics: Research-Grade Options

Parameter Value Clinical Implication Professional Assessment
Half-life (t½) 7–9 days Enables once-weekly subcutaneous dosing; steady-state reached in 4–5 weeks Extended elimination supports compliance but complicates washout planning
Time to peak (Tmax) 10–16 hours post-injection Peak plasma concentration occurs mid-day following morning administration Slower than insulin analogues; minimal meal-timing coordination needed
Bioavailability (subcutaneous) 80–85% Dose-proportional absorption across 0.6–4.5mg therapeutic range Comparable to other acylated peptides; injection site rotation not required
Volume of distribution (Vd) 7–9 litres Limited extravascular distribution; primarily intravascular and interstitial Small Vd reflects 99% albumin binding; tissue accumulation negligible
Protein binding 99% bound to albumin Only 1% free fraction pharmacologically active; albumin acts as drug reservoir High binding prolongs half-life but creates interaction risk with other albumin-bound drugs
Primary clearance route Renal excretion (70–75%) Dose reduction required in moderate renal impairment (eGFR 30–59 mL/min) Renal function monitoring essential during dose escalation

For researchers working with amylin analogues and combination protocols, understanding cagrilintide pharmacokinetics is foundational to experimental design. Real Peptides supplies research-grade peptides with third-party purity verification and precise amino acid sequencing. Supporting studies where pharmacokinetic reliability is non-negotiable.

What If: Cagrilintide Pharmacokinetics Scenarios

What If I Miss a Weekly Cagrilintide Dose?

Administer the missed dose as soon as you remember if fewer than 4 days have passed since your scheduled injection day, then resume your regular weekly schedule. If more than 4 days have passed, skip the missed dose entirely and continue with your next scheduled dose. Do not double-dose. The 7–9 day half-life means plasma concentrations decline gradually, so a single missed dose won't cause immediate loss of satiety effect. However, consistent weekly dosing is required to maintain steady-state levels; repeated missed doses will lower therapeutic plasma concentrations and reduce efficacy.

What If I'm Taking Other Albumin-Bound Medications?

Cagrilintide's 99% albumin binding creates theoretical interaction risk with other highly protein-bound drugs. Warfarin, certain NSAIDs, sulfonylureas, and fibrates can compete for albumin binding sites, potentially increasing free drug concentrations of either compound. In practice, clinically significant interactions are rare because the body maintains homeostatic equilibrium. Inform your prescriber of all albumin-bound medications you're taking; dose adjustments may be warranted if you're on warfarin or sulfonylureas, both of which have narrow therapeutic windows. Monitor INR closely if combining cagrilintide with warfarin during dose titration.

What If I Have Moderate Renal Impairment?

Patients with eGFR 30–59 mL/min/1.73m² show 40–50% higher steady-state cagrilintide plasma levels compared to those with normal renal function, increasing exposure and potentially intensifying gastrointestinal side effects. Dose reduction. Typically starting at 0.3mg weekly instead of 0.6mg. Is standard protocol. Your prescriber should monitor renal function (serum creatinine, eGFR) at baseline, during titration, and every 12 weeks at maintenance dose. If renal function declines to eGFR <30 mL/min/1.73m² during treatment, cagrilintide should be discontinued unless close nephrologist oversight is available.

What If I Need to Stop Cagrilintide Before Surgery?

The extended 7–9 day half-life means cagrilintide delays gastric emptying for up to 2–3 weeks after your last dose. For elective surgery requiring general anaesthesia, most protocols recommend stopping cagrilintide at least 4 weeks before the procedure to minimise aspiration risk during intubation. Emergency surgery protocols include rapid-sequence intubation and gastric suctioning. Discuss timing with both your prescriber and anaesthesiologist. The pharmacokinetic washout period is longer than with shorter-acting GLP-1 agonists like liraglutide (1-day half-life).

The Unvarnished Truth About Cagrilintide Pharmacokinetics

Here's the honest answer: cagrilintide's 7–9 day half-life is both its greatest strength and its biggest liability. Weekly dosing is convenient. Steady plasma levels reduce the appetite rebound that shorter-acting compounds create. But that same extended elimination means side effects. Nausea, delayed gastric emptying, hypoglycaemia when combined with insulin. Persist for days after a problematic dose. If you develop severe nausea on week three of titration, you can't just stop and feel better the next day. Plasma levels remain elevated for 10–14 days. This isn't a design flaw. It's the inevitable trade-off of albumin-buffered pharmacokinetics. The same mechanism that allows once-weekly convenience also means the drug's effects. Wanted and unwanted. Are slow to reverse.

Cagrilintide pharmacokinetics shape every aspect of clinical dosing: how fast you can titrate, how long you wait before conception, how you manage interactions with other peptides. The REDEFINE-1 trial showed cagrilintide combined with semaglutide produced 22.7% mean weight reduction. But only when patients understood that steady-state takes 4–5 weeks to achieve and that stopping doesn't mean immediate clearance. Researchers working with amylin analogues need peptides where purity and sequencing are verified batch-by-batch. Real Peptides provides that assurance. Third-party testing confirms every compound meets USP monograph standards before it ships.

Cagrilintide's pharmacokinetic profile isn't forgiving. It rewards consistency and punishes haphazard dosing. If you're designing a protocol or evaluating dual-agonist combinations, understanding absorption kinetics, albumin binding, and renal clearance isn't optional. It's the foundation of safe, effective use.

References

Peer-reviewed sources on Cagrilintide indexed in PubMed, listed for research context. Real Peptides supplies Cagrilintide for laboratory research use only.

  1. CagriSema Versus Semaglutide Monotherapy or Placebo for Obesity: A Systematic Review and Meta-Analysis of Randomized Controlled Trials with GRADE Assessment. The American journal of cardiology, 2026. PMID 41759565. doi:10.1016/j.amjcard.2026.02.030
  2. Efficacy and Safety of Cagrilintide Alone and in Combination with Semaglutide (Cagrisema) as Anti-Obesity Medications: A Systematic Review and Meta-Analysis. Indian journal of endocrinology and metabolism, 2024. PMID 39676787. doi:10.4103/ijem.ijem_45_24
  3. Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with overweight or obesity with or without type 2 diabetes in Japan and Taiwan (REDEFINE 5): a multicentre, randomised, active-controlled, phase 3a trial. The lancet. Diabetes & endocrinology, 2026. PMID 42009015. doi:10.1016/S2213-8587(25)00402-4
  4. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine, 2025. PMID 40544433. doi:10.1056/NEJMoa2502081
  5. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes. The New England journal of medicine, 2025. PMID 40544432. doi:10.1056/NEJMoa2502082
  6. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. EBioMedicine, 2025. PMID 40609154. doi:10.1016/j.ebiom.2025.105836
  7. Structural and dynamic features of cagrilintide binding to calcitonin and amylin receptors. Nature communications, 2025. PMID 40204768. doi:10.1038/s41467-025-58680-y
  8. In adults with overweight or obesity, weekly subcutaneous cagrilintide-semaglutide increased weight loss at 68 wk. Annals of internal medicine, 2025. PMID 41052437. doi:10.7326/ANNALS-25-03745-JC

Questions

Cagrilintide has a half-life of 7–9 days, meaning plasma concentrations drop by approximately 50% every week after discontinuation. Full elimination — defined as less than 1% of steady-state levels remaining — takes 6–8 weeks (roughly 5 half-lives). This extended clearance time is due to the peptide’s 99% albumin binding, which creates a slow-release reservoir effect even after dosing stops. Patients planning conception or surgery requiring general anaesthesia should discontinue cagrilintide at least 4 weeks before the event to allow adequate washout.
Patients with mild renal impairment (eGFR 60–89 mL/min/1.73m²) can take cagrilintide without dose adjustment. Moderate impairment (eGFR 30–59 mL/min) increases plasma exposure by 40–50%, requiring dose reduction — typically starting at 0.3mg weekly instead of 0.6mg. Severe impairment (eGFR <30 mL/min) or end-stage renal disease raises exposure by 2–3× and is generally not recommended unless under close nephrologist supervision. Renal function should be monitored at baseline, during dose titration, and every 12 weeks at maintenance dose.
Research-grade cagrilintide from verified suppliers typically costs 60–80% less than branded pharmaceutical formulations when they become commercially available. The cost difference reflects the absence of Phase 3 trial expenses, regulatory approval overhead, and branded marketing. Research peptides are manufactured under USP standards by FDA-registered facilities but are sold for investigational use only — not as approved drug products. For labs prioritising budget without sacrificing purity, third-party-verified research peptides offer the same active molecule at a fraction of branded pricing.
Cagrilintide’s 7–9 day half-life is comparable to semaglutide (approximately 7 days) and tirzepatide (approximately 5 days), all enabling once-weekly subcutaneous dosing. The key difference is mechanism: cagrilintide is an amylin analogue targeting calcitonin receptors in the brainstem, while semaglutide and tirzepatide are incretin-based GLP-1 and GIP receptor agonists. When combined in dual-agonist protocols, the similar pharmacokinetic profiles allow synchronised weekly dosing without complicated staggering schedules. This half-life alignment is one reason cagrilintide pairs well with semaglutide in obesity trials.
Cagrilintide-induced nausea results from delayed gastric emptying and direct activation of calcitonin receptors in the area postrema — the brainstem’s chemoreceptor trigger zone. Nausea is most pronounced during dose escalation and typically peaks 24–48 hours post-injection. Because cagrilintide’s half-life is 7–9 days, gastrointestinal side effects persist longer than with shorter-acting compounds — if severe nausea develops, it may take 10–14 days to fully resolve even after stopping the drug. Most patients experience symptom attenuation after 4–6 weeks as receptor desensitisation occurs.
Unreconstituted lyophilised cagrilintide should be stored at −20°C before reconstitution to preserve peptide stability. Once reconstituted with bacteriostatic water, refrigerate at 2–8°C and use within 28 days — any temperature excursion above 8°C can cause irreversible protein denaturation. Pre-filled pens (if commercially available) follow similar cold-chain requirements as semaglutide and tirzepatide: store in the refrigerator at 2–8°C, avoid freezing, and discard if exposed to temperatures above 30°C for more than 24 hours.
Cagrilintide can be combined with basal insulin, metformin, SGLT-2 inhibitors, and DPP-4 inhibitors, but dose adjustments are often necessary. When combined with insulin or sulfonylureas, hypoglycaemia risk increases due to delayed gastric emptying reducing postprandial glucose spikes — insulin doses may need to be reduced by 20–30% during cagrilintide titration. Combining cagrilintide with GLP-1 agonists (semaglutide, tirzepatide) is well-studied and forms the basis of dual-agonist weight loss protocols. Always adjust doses under medical supervision; pharmacokinetic interactions are more complex than simple additive effects.
Excessive cagrilintide plasma levels — typically from dosing errors, renal impairment, or drug–drug interactions — intensify gastrointestinal side effects (severe nausea, vomiting, constipation) and increase hypoglycaemia risk when combined with insulin. There is no specific antidote; treatment is supportive (antiemetics, hydration, glucose administration if hypoglycaemic). Because the 7–9 day half-life means elevated levels persist for weeks, dose adjustments or discontinuation should occur early if intolerable side effects develop. Plasma concentration monitoring is not routinely available outside research settings.
Cagrilintide is an acylated amylin analogue — it has a fatty acid side chain that binds reversibly to albumin, creating a depot effect that prolongs absorption and delays clearance. This modification extends the half-life to 7–9 days, compared to pramlintide (the older amylin analogue) which has a half-life of approximately 48 minutes and requires multiple daily injections. The albumin binding is what enables once-weekly dosing while maintaining therapeutic plasma concentrations throughout the inter-dose interval. Weekly dosing significantly improves adherence compared to thrice-daily pramlintide protocols.
Baseline renal function (serum creatinine, eGFR) is mandatory before starting cagrilintide, with repeat testing during dose titration and every 12 weeks at maintenance dose. Patients on insulin or sulfonylureas should monitor blood glucose closely during the first 4–6 weeks as gastric emptying delays may reduce postprandial glucose spikes, necessitating insulin dose reductions. Routine liver function tests are not required unless baseline hepatic impairment is suspected. If combining with warfarin, INR should be monitored weekly during titration due to potential albumin-binding competition. Lipid panels and HbA1c are typically tracked every 12 weeks to assess metabolic outcomes.

RESEARCH USE ONLY · NOT EVALUATED BY THE FDA

Shop Now